

Supplemental Digital Table B: The frequency (% athlete assessments) of residual symptoms, abnormal clinical signs/laboratory investigations and cardiac magnetic resonance imaging for participants in three different subgroups based on total number of acute symptoms (individual variables)

Variables, n	Subgroup 1 (asymptomatic or ≤5 acute symptoms) (n=29)	Subgroup 2 (6-9 acute symptoms) (n=34)	Subgroup 3 (≥10 acute symptoms) (n=32)	p-value (2 vs. 1)	p-value (3 vs. 1)	p-value (All subgroups)
SECTION B1						
RESIDUAL SYMPTOMS^a (n=96)						
Cardiovascular						
Chest pain	0	3 (9.1) ^b	9 (28.1)	-	-	-
Racing heart	1 (3.3)	10 (29.4)	11 (34.4)	-	-	-
Irregular heartbeats	0	1 (2.9)	3 (9.4)	-	-	-
Respiratory						
<i>Upper respiratory</i>						
Sore throat	2 (6.7)	3 (8.8)	-	-	-	-
Hoarseness	0	1 (2.9)	-	-	-	-
Blocked nose	4 (13.3)	3 (8.8)	12 (37.5)	-	-	-
Runny nose	2 (6.7)	3 (8.8)	6 (18.8)	-	-	-
Sinus pressure	3 (10.0)	7 (20.6)	9 (28.1)	0.415	0.135	0.212
Sneezing	4 (13.3)	3 (8.8)	2 (6.3)	-	-	-
Other [†]	1 (3.3)	1 (2.9)	3 (9.4)	-	-	-
<i>Lower respiratory^c</i>						
Dry cough	3 (10.0)	9 (26.5)	10 (31.3)	0.17	0.078	0.119
Wet cough	0	5 (14.7)	6 (18.8)	-	-	-
Dyspnoea	1 (3.3)	4 (11.8)	10 (31.3)	-	-	-
Shortness of breath	7 (23.3)	12 (35.3)	13 (40.6)	0.442	0.236	0.357
Chest tightness	1 (3.3)	7 (20.6)	7 (21.9)	-	-	-
Other (trachea feels constricted)	0	1 (2.9)	0	-	-	-
Neurological						
Headache	2 (6.7)	6 (18.2) ^b	10 (31.3)	-	-	-
Excessive fatigue	1 (3.3)	9 (26.5)	12 (37.5)	-	-	-
Dizziness	0	3 (8.8)	5 (15.6)	-	-	-
Nerve tingling	0	0	1 (3.3) ^a	-	-	-
Balance/coordination problems	0	1 (2.9)	3 (9.7) ^b	-	-	-
Altered/loss sense of smell	9 (30.0)	5 (14.7)	12 (37.5)	0.241	0.724	0.105
Altered/loss sense of taste	7 (23.3)	5 (14.7)	11 (34.4)	0.574	0.499	0.186

Other ‡	1 (3.3)	4 (11.8)	7 (21.9)	-	-	-
Gastrointestinal						
Abdominal pain	0	2 (5.9)	2 (6.3)	-	-	-
Nausea	1 (3.3)	0	3 (9.4)	-	-	-
Vomiting	0	0	0	-	-	-
Diarrhoea	1 (3.3)	1 (3.0) ^b	0	-	-	-
Loss of appetite	1 (3.3)	3 (8.8)	3 (9.4)	-	-	-
Musculoskeletal						
Muscle	0	3 (8.8)	7 (21.9)	-	-	-
Myalgia	0	0	4 (12.5)	-	-	-
Muscles cramps	0	1 (2.9)	0	-	-	-
Muscle stiffness	0	3 (8.8)	4 (12.5)	-	-	-
Joint	0	1 (2.9)	1 (3.1)	-	-	-
Joint pains	0	1 (2.9)	1 (3.1)	-	-	-
Ocular						
Red/scratchy eyes	0	3 (9.1) ^b	1 (3.2) ^b	-	-	-
Other (dry eyes)	0	0	1 (1.0)	-	-	-
Systemic						
Fever/Chills	0	0	0	-	-	-
SECTION B2						
ANY ABNORMAL CLINICAL SIGN^d (n=96)						
Cardiovascular^e						
Resting HR >100 bpm, SBP >200 mm Hg ^f , pericardial rub ^a , raised JVP ^f , DVT ^f	0	0	0			
Respiratory						
Oxygen saturation <90%	0	0	0			
<i>Upper respiratory^g</i>						
Tympanic membrane bulging/absence light cone	7 (24.1) ^b	5 (15.2) ^b	7 (22.6) ^b	0.567	1	0.653
Sinus tenderness	2 (6.7)	2 (5.9)	10 (33.3) ^a	-	-	-
Posterior pharynx erythema/enanthema/sores	0 ^a	1 (2.9)	2 (6.5) ^b	-	-	-
Tonsillar erythema/sores	0	0	0			
<i>Lower respiratory</i>						
Abnormal breath sounds	0	0	0			
Neurological						
Neck stiffness	0	0	0			
Gastrointestinal						
Abdominal tenderness (epigastric, RUQ, LUQ, periumbilical, right and left iliac fossa) ^h	0 ^c	3 (9.1) ^b	6 (19.4) ^b	-	-	-
Skin						

Skin rash/ discolouration	0	1 (2.9)	1 (3.1)	-	-	-
Ocular						
Conjunctivitis	0	2 (6.1) ^h	1 (3.2) ^h	-	-	-
Systemic						
Fever	0	0	0			
SECTION B3						
ANY ABNORMAL LABORATORY INVESTIGATION (n=96)						
Cardiovascular						
<i>Electrocardiogram (ECG) (Any)</i>	3 (10.0)	4 (11.8)	2 (6.3)	0.734	1	0.739
Resting ECG	2 (6.7)	0	0	0.734	1	0.739
Submaximal exercise ECG ^b	1 (3.5) ^b	4 (11.8)	2 (6.3)	0.734	1	0.739
<i>ECHO (Any)</i>	2 (6.7)	1 (3.0) ^b	0	0.734	1	0.739
Decreased LVEF	0	0	0	0.734	1	0.739
LV wall motion abnormalities	1 (3.3)	1 (3.0) ^b	0	0.734	1	0.739
Pericardial effusion	0	0	0	-	-	-
Left ventricular dysfunction	1 (3.3)	0 ^b	0	-	-	-
<i>hs-TnT^a</i>	0	0	0	-	-	-
Respiratory						
<i>Resting PFT</i>	0	4 (12.1) ^b	2 (6.5) ^b	-	-	-
FEV ₁ < LLN	0	1 (3.0) ^b	1 (3.2) ^b	-	-	-
FVC< LLN	0	2 (6.1) ^b	1 (3.2) ^b	-	-	-
FEV ₁ /FVC < LLN	0	2 (6.1) ^b	1 (3.2) ^b	-	-	-
Gastrointestinal						
AST	4 (13.3)	4 (11.8)	8 (25.0)	1	0.402	0.299
ALT	2 (6.7)	3 (8.8)	9 (28.1)	-	-	-
Musculoskeletal						
Creatine kinase ^c	3 (10.0)	3 (9.4) ^a	4 (12.9) ^b	1	1	0.919
Immune/blood system						
WCC	2 (6.7)	2 (5.9)	2 (6.3)	-	-	-
Neutrophil count	4 (13.3)	1 (2.9)	2 (6.3)	-	-	-
Lymphocyte count (n=96)	0	0	0	-	-	-
CRP (n=95)	1 (3.3)	0 ^b	0	-	-	-
SECTION B4						
ANY ABNORMAL CMR (n=65)						
Myocardial LGE	1 (6.7)	6 (25.0)	6 (23.1)	-	-	-
Pericardial LGE	0	5 (20.8)	3 (11.5)	-	-	-
Pericardial effusion 5-10 mm	1 (6.7)	3 (12.5)	3 (11.5)	-	-	-
Pericardial effusion >10mm	0	1 (4.2)	0	-	-	-
Decreased LVEF	2 (13.3)	0	1 (3.9)	-	-	-
Wall motion abnormalities	0	0	1 (3.9)	-	-	-

T1 mapping	0	1 (4.2)	0	-	-	-
T2 mapping	0	1 (4.2)	0	-	-	-
Myocarditis (Lake Louise criteria)	0	1 (4.2)	0	-	-	-

- Numbers too small to test statistical significance

† Post nasal drip, bilateral earache, and 'blocked' ears

‡ Sleep disturbances, feeling slow, mood swings, irritable, increased anxiety, 'brain fog', slight hearing loss, tires easily, lightheaded, forgetful

HR, heart rate; bpm, beats per minute; SBP, systolic blood pressure; mmHg, millimetre mercury; JVP, jugular venous pressure; DVT, deep vein thrombosis; RUQ, right upper quadrant; LUQ, left upper quadrant, ECHO, echocardiogram; LVEF, left ventricular ejection fraction; LV, left ventricle; CMR, cardiac magnetic resonance imaging, LGE, late gadolinium enhancement; hs-Trop T, high-sensitivity Troponin T; PFT, pulmonary function test; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; LLN, lower limit of normal; AST, aspartate transaminase; ALT, alanine transaminase; WCC, white cell count; CRP, C-reactive protein

Missing data on participants: a=2; b=1, c=3, d=15, e=7, f=6, g=9, h=5